VALANX Biotech GmbH has formed a board of directors as the company moves from a research-stage organisation into clinical development and technology commercialisation. The chairman is Michael Boehler. His more than 20 years’ experience includes being vice president global commercial and general manager at BioNTech, where he helped drive the company’s evolution from a clinical stage biotech to a market leader through the launch of the first mRNA COVID-19 vaccine. Dr Boehler is currently chief business officer at clock.bio. The board’s directors are: Alexander Schwartz, currently a partner at Xista Science Ventures; Urs Spitz, chief executive officer and co-owner of Biosynth; and Ingo S. Nagler, co-owner of VALANX and a biotech investor.
VALANX Biotech announced the appointments on 10 December 2025.
Copyright 2026 Evernow Publishing Ltd.